Lunes 24 de de Junio 2019

Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform

FRAMINGHAM, Mass.–(BUSINESS WIRE)–#ACMG–Variantyx announced the US launch of its proprietary clinical diagnostic
platform at the American College of Medical Genetics (ACMG) conference
in Phoenix, AZ. The Genomic
® platform automates the complete NGS testing
process from sample collection to sequencing, data analysis,
interpretation and clinical report generation, allowing ordering
physicians to focus on making a diagnosis with the interactive support
of Variantyx’ US Board Certified Geneticists. The end-to-end clinical
diagnostic services are errors and omissions insured, HIPAA and CLIA

As part of the US market launch, Variantyx is offering to review
previously undiagnosed cases and provide a second opinion to clinicians
at no cost. All clinicians have to do is authorize the testing
laboratories to send the FASTQ or BAM files from whole exome, whole
genome or panel sequencing and Variantyx will provide a clinical report
of their findings.

Variantyx CEO Haim Neerman states: “ Widely used by several hospitals
around the world, the Genomic Intelligence® platform has
processed thousands of samples and solved many previously undiagnosed,
complex cases. Clinicians have nothing to lose, and patients have
everything to gain, by getting a second opinion.” He welcomes the
challenge and encourages clinicians to submit their unsolved cases at

Dr. Virginia Kimonis, Principal Investigator at the Division of Genetics
and Genomics Medicine at UC Irvine School of Medicine states: “I was
surprised how fast and easy it was to resolve my cases. The Genomic
Intelligence® platform utilizes the best available public,
proprietary and in-house developed resources to detect and report
clinically actionable variants. The user-friendly console enables
variant selection and clinical report generation so quickly, allowing
one to review more cases in a single day.”

About Variantyx: Specializing in whole genome analysis, Variantyx offers
clinicians, hospitals and labs a comprehensive set of products and
services for diagnosing rare genetic disorders. For more information,
please visit


Muthu Meyyappan, 617-209-2090 or 978-821-2399